Nathaniel Gaeckle, Edward Corazalla, Judy S Kelloway, Joshua N Liberman, Jonathan David Darer, Kristin Kahle-Wrobleski, Rosirene Paczkowski, Purva Parab, Charles Ruetsch
{"title":"电子病历支持的慢性阻塞性肺病评估测试的真实世界评估。","authors":"Nathaniel Gaeckle, Edward Corazalla, Judy S Kelloway, Joshua N Liberman, Jonathan David Darer, Kristin Kahle-Wrobleski, Rosirene Paczkowski, Purva Parab, Charles Ruetsch","doi":"10.2147/COPD.S479853","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) measures COPD's impact on well-being and daily activities and is a recommended assessment by the Global Initiative for Obstructive Lung Disease (GOLD). Our research objective was to describe a real-world CAT implementation, including the association of CAT scores with subsequent treatment and clinical outcomes.</p><p><strong>Patients and methods: </strong>A retrospective, observational, comparative cohort study was conducted among adults with COPD who received care from M Health Fairview, a US healthcare delivery system. Eligible patients had an initial electronic health record (EHR) enabled CAT administration (index) between 8/2017 and 12/2021. Patients were grouped by score (<10 [low impact]; 11-20 [moderate]; and 21-40 [high]). Demographics, comorbidities, provider specialty, and exacerbation history were derived from EHR data in the 12 months preceding index.</p><p><strong>Results: </strong>Of 11,194 eligible individuals, 821 (7.3%) were administered CAT (cases). Compared to individuals with no documented CAT scores (comparators), cases were older (66.7 vs 63.9 years; <i>p</i> < 0.05) and had higher rates of comorbidities (93.9% vs 79.2%, <i>p</i> < 0.05) and exacerbations (0.31 vs 0.14 PPPY). A total of 61.5% of pulmonologists and 11.5% of primary care providers (PCPs) administered the CAT at least once. Repeated use was more common among pulmonologists (55.7%) than PCPs (7.0%). Medication intensification was most common (28.1%) among individuals with high CAT scores, followed by moderate (21.6%), and low (10.0%). Post-index exacerbations were experienced by 24.2%, 17.4%, and 7.7% of patients with high, moderate, and low CAT scores.</p><p><strong>Conclusion: </strong>In a real-world practice setting, few patients with COPD received a CAT, although pulmonologists demonstrated repeated use. Higher CAT scores were associated with COPD medication regimen intensification and exacerbations. Further investigation on how to incorporate the CAT into routine care and optimize its impact on medical decision making and evaluation is warranted.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"325-334"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835772/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-World Evaluation of an EHR-Enabled Chronic Obstructive Pulmonary Disease Assessment Test.\",\"authors\":\"Nathaniel Gaeckle, Edward Corazalla, Judy S Kelloway, Joshua N Liberman, Jonathan David Darer, Kristin Kahle-Wrobleski, Rosirene Paczkowski, Purva Parab, Charles Ruetsch\",\"doi\":\"10.2147/COPD.S479853\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) measures COPD's impact on well-being and daily activities and is a recommended assessment by the Global Initiative for Obstructive Lung Disease (GOLD). Our research objective was to describe a real-world CAT implementation, including the association of CAT scores with subsequent treatment and clinical outcomes.</p><p><strong>Patients and methods: </strong>A retrospective, observational, comparative cohort study was conducted among adults with COPD who received care from M Health Fairview, a US healthcare delivery system. Eligible patients had an initial electronic health record (EHR) enabled CAT administration (index) between 8/2017 and 12/2021. Patients were grouped by score (<10 [low impact]; 11-20 [moderate]; and 21-40 [high]). Demographics, comorbidities, provider specialty, and exacerbation history were derived from EHR data in the 12 months preceding index.</p><p><strong>Results: </strong>Of 11,194 eligible individuals, 821 (7.3%) were administered CAT (cases). Compared to individuals with no documented CAT scores (comparators), cases were older (66.7 vs 63.9 years; <i>p</i> < 0.05) and had higher rates of comorbidities (93.9% vs 79.2%, <i>p</i> < 0.05) and exacerbations (0.31 vs 0.14 PPPY). A total of 61.5% of pulmonologists and 11.5% of primary care providers (PCPs) administered the CAT at least once. Repeated use was more common among pulmonologists (55.7%) than PCPs (7.0%). Medication intensification was most common (28.1%) among individuals with high CAT scores, followed by moderate (21.6%), and low (10.0%). Post-index exacerbations were experienced by 24.2%, 17.4%, and 7.7% of patients with high, moderate, and low CAT scores.</p><p><strong>Conclusion: </strong>In a real-world practice setting, few patients with COPD received a CAT, although pulmonologists demonstrated repeated use. Higher CAT scores were associated with COPD medication regimen intensification and exacerbations. Further investigation on how to incorporate the CAT into routine care and optimize its impact on medical decision making and evaluation is warranted.</p>\",\"PeriodicalId\":48818,\"journal\":{\"name\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"volume\":\"20 \",\"pages\":\"325-334\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835772/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/COPD.S479853\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S479853","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
目的:慢性阻塞性肺疾病(COPD)评估测试(CAT)衡量COPD对健康和日常活动的影响,是全球阻塞性肺疾病倡议(GOLD)推荐的评估。我们的研究目的是描述一个真实世界的CAT实施,包括CAT评分与后续治疗和临床结果的关联。患者和方法:一项回顾性、观察性、比较队列研究在接受美国医疗保健服务系统M Health Fairview护理的成人COPD患者中进行。符合条件的患者在2017年8月至2021年12月期间进行了初始电子健康记录(EHR)启用CAT管理(索引)。结果:在11194例符合条件的患者中,821例(7.3%)接受了CAT治疗。与没有记录CAT评分的个体(比较者)相比,病例年龄较大(66.7 vs 63.9岁;p < 0.05),合并症发生率(93.9%比79.2%,p < 0.05)和加重率(0.31比0.14 PPPY)较高。共有61.5%的肺科医生和11.5%的初级保健提供者(pcp)至少进行过一次CAT。重复用药在肺科医生(55.7%)中比pcp(7.0%)更常见。在CAT评分高的个体中,药物强化最为常见(28.1%),其次是中度(21.6%)和低(10.0%)。高、中、低CAT评分患者的指数后加重发生率分别为24.2%、17.4%和7.7%。结论:在现实世界的实践环境中,很少有COPD患者接受CAT,尽管肺科医生证明了反复使用。较高的CAT评分与COPD用药方案的加重和恶化有关。进一步研究如何将CAT纳入日常护理并优化其对医疗决策和评估的影响是有必要的。
Real-World Evaluation of an EHR-Enabled Chronic Obstructive Pulmonary Disease Assessment Test.
Purpose: The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) measures COPD's impact on well-being and daily activities and is a recommended assessment by the Global Initiative for Obstructive Lung Disease (GOLD). Our research objective was to describe a real-world CAT implementation, including the association of CAT scores with subsequent treatment and clinical outcomes.
Patients and methods: A retrospective, observational, comparative cohort study was conducted among adults with COPD who received care from M Health Fairview, a US healthcare delivery system. Eligible patients had an initial electronic health record (EHR) enabled CAT administration (index) between 8/2017 and 12/2021. Patients were grouped by score (<10 [low impact]; 11-20 [moderate]; and 21-40 [high]). Demographics, comorbidities, provider specialty, and exacerbation history were derived from EHR data in the 12 months preceding index.
Results: Of 11,194 eligible individuals, 821 (7.3%) were administered CAT (cases). Compared to individuals with no documented CAT scores (comparators), cases were older (66.7 vs 63.9 years; p < 0.05) and had higher rates of comorbidities (93.9% vs 79.2%, p < 0.05) and exacerbations (0.31 vs 0.14 PPPY). A total of 61.5% of pulmonologists and 11.5% of primary care providers (PCPs) administered the CAT at least once. Repeated use was more common among pulmonologists (55.7%) than PCPs (7.0%). Medication intensification was most common (28.1%) among individuals with high CAT scores, followed by moderate (21.6%), and low (10.0%). Post-index exacerbations were experienced by 24.2%, 17.4%, and 7.7% of patients with high, moderate, and low CAT scores.
Conclusion: In a real-world practice setting, few patients with COPD received a CAT, although pulmonologists demonstrated repeated use. Higher CAT scores were associated with COPD medication regimen intensification and exacerbations. Further investigation on how to incorporate the CAT into routine care and optimize its impact on medical decision making and evaluation is warranted.
期刊介绍:
An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals